Psychedelics UC San Diego receives US$1.5M for cognitive research on DMT Fund supporting the institution's Psychedelics and Health Research Initiative was provided by philanthropist Eugene Jhong Rowan DunneJuly 11, 2023
Psychedelics FDA publishes first draft guidance document for psychedelics research It aims to highlight relevant considerations for researchers investigating the therapeutic value of psychedelics Rowan DunneJune 23, 2023
News Algernon Pharmaceuticals completes final dosing in DMT study for stroke and TBI treatment AGN Neuro plans to publish the data from the study in an upcoming issue of a peer-reviewed paper Natalia Buendia CalvilloJune 5, 2023
News Colorado governor signs bill regulating psychedelics The Natural Medicine Health act will take effect on July 1 Natalia Buendia CalvilloMay 26, 2023
News NIH invests $1.5M in psychedelics research for substance use disorders Research teams can receive up to $700K for an initial two-year phase to develop their studies, followed by up to $500K per year for... Natalia Buendia CalvilloMay 19, 2023
Psychedelics New York legislators introduce bill to legalize natural psychedelics Bill A00114 would legalize adult possession and use of ibogaine, mescaline, psilocybin and psilocin Natalia Buendia CalvilloJanuary 3, 2023
Psychedelics Colorado votes to decriminalize use and possession of natural psychedelics It also introduces state-regulated 'healing centers' where trained facilitators can offer psychedelic-assisted sessions Natalia Buendia CalvilloDecember 29, 2022
Canada PsyCan aims to be ‘go-to’ psychedelics industry organization, receives support from lawmakers The non-profit trade association received a high level of interest from multiple branches of government Rowan DunneNovember 10, 2022
Psychedelics Small Pharma gets approval for upcoming injectable DMT trial on humans New phase I study will be held at MAC Clinical Research in Manchester, England next year Rowan DunneOctober 31, 2022
Psychedelics Algernon partners with Yale University for phase II DMT study Algernon will provide cGMP DMT for the study in exchange for part-ownership of IP generated Rowan DunneOctober 24, 2022